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Background: A recent animal study showed that parathyroid hormone-related peptide (PTHrP) is associated with cancer cachexia 
by promoting adipose tissue browning, and we previously demonstrated that PTHrP predicts weight loss (WL) in patients with cancer. 
In this study, we investigated whether prediction of WL by PTHrP is influenced by clinical factors such as serum albumin, corrected 
calcium levels, cancer stage, and performance status (PS).
Methods: A cohort of 219 patients with cancer whose PTHrP level was measured was enrolled and followed for body weight (BW) 
changes. Subjects were divided into two groups by serum albumin (cutoff value, 3.7 g/dL), corrected calcium (cutoff value, 10.5 mg/dL), 
cancer stage (stage 1 to 3 or 4), or PS (Eastern Cooperative Oncology Group 0 to 1 or 2 to 4), respectively. Clinically significant WL 
was defined as either percent of BW change (% BW) <–5% or % BW <–2% plus body mass index (BMI) <20 kg/m2.
Results: After a median follow-up of 327 days, 74 patients (33.8%) experienced clinically significant WL. A positive PTHrP level 
was associated with a 2-fold increased risk of WL after adjusting for age, baseline BMI, serum albumin, corrected calcium level, 
cancer stage, and PS. The effect of PTHrP on WL remained significant in patients with low serum albumin, stage 4 cancer, and good 
PS. Regardless of calcium level, the effect of PTHrP on WL was maintained, although there was an additive effect of higher calcium 
and PTHrP levels.
Conclusion: Early recognition of patients with advanced cancer who are PTHrP positive with hypercalcemia or hypoalbuminemia is 
needed for their clinical management.
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INTRODUCTION
Cachexia is a wasting disorder that occurs secondarily in pa-
tients with chronic diseases such as cancer, congestive heart 
failure (CHF), and chronic kidney disease [1]. The prevalence 
of cachexia among patients with cancer is about 50% to 80% [2] 
and is characterized by involuntary loss of skeletal muscle (with 
or without loss of fat mass), reduced food intake, and negative 
energy balance [1,3]. It is distinct from age-related muscle loss 
or malnutrition in that it cannot be reversed by increasing nutri-
tional intake, since metabolic dysfunction and increased catabo-
lism play roles in the pathogenesis of cancer cachexia [4,5]. 
Parathyroid hormone-related peptide (PTHrP) plays a number 
of paracrine roles in many tissues under normal conditions [6]. 
However, when it is secreted by a tumor and enters the circula-
tion, it stimulates bone resorption, leading to hypercalcemia of 
malignancy [7]. Furthermore, recent studies revealed that 
PTHrP plays an important role in cancer cachexia by activating 
thermogenesis via adipose tissue browning, while neutralization 
of PTHrP blocked wasting of fat and skeletal muscle in mice 
models with cancer [8].
Previously, we demonstrated that PTHrP was associated with 
weight loss (WL) in cancer patients, suggesting that PTHrP may 
be a predictor of cancer cachexia [9]. In this study, we further 
investigated whether prediction of WL by PTHrP is influenced 
by other factors such as serum albumin, corrected calcium lev-
els, cancer stage, and performance status (PS). 
METHODS
Study design and population 
The study population was derived from the SECRET (SEver-
ance CanceR cachExia neTwork) cohort, who were patients 
treated at a medical oncology department at Severance Hospital, 
Yonsei University College of Medicine (a tertiary-level cancer 
treatment center), as previously described [9]. Adults >18 years 
of age whose serum PTHrP levels were measured between No-
vember 2005 and June 2014 (n=624) were considered for inclu-
sion; excluded were patients with missing serum albumin or 
corrected calcium values and those whose body weight (BW) 
was not measured repeatedly during the follow-up period. A to-
tal of 219 eligible subjects were included in the analysis, with a 
median follow-up period of 327 days for BW changes (inter-
quartile range [IQR], 188 to 423 days). 
Subjects were classified into two groups by serum albumin 
levels (≥3.7 or <3.7 g/dL), corrected calcium levels (<10.5 or 
≥10.5 mg/dL), cancer stage (stage 1 to 3 or stage 4), or PS 
(Eastern Cooperative Oncology Group [ECOG] 0 to 1 or 2 to 4), 
respectively. This study was approved by the Institutional Re-
view Board of the Yonsei University Health System, Severance 
Hospital (No. 4-2015-0246). Informed consent was exempted 
because personal identifying information was not accessed. 
Measurements of clinical and laboratory parameters 
Baseline data including age, sex, cancer stage, ECOG PS, and 
comorbidities such as CHF, chronic obstructive pulmonary dis-
ease, diabetes mellitus, and liver cirrhosis were examined 
through electronic medical records review. Cancer stage was 
defined according to the American Joint Committee on cancer 
stage grouping (stage I, II, III, and IV). 
Serum PTHrP was quantified by means of immunoradiomet-
ric assay (IRMA; Allegro IRMA, Nichols Institute, San Juan 
Capistrano, CA, USA) [10] with a detection limit of 0.5 pmol/L. 
Serum calcium, phosphate, albumin, and hemoglobin were 
measured by standard techniques. Corrected calcium was calcu-
lated according to the formula: measured serum calcium+[0.8×
(4.0–albumin [g/dL] if serum albumin <4.0)]. Serum creatinine 
and C-reactive protein (CRP) were examined by Hitachi 7600-
110 automated chemistry analyzer (Hitachi Co., Tokyo, Japan). 
Estimated glomerular filtration rate was determined using 
Chronic Kidney Disease-Epidemiology Collaboration (CKD-
EPI) equation [11].
Definition of weight loss 
We measured BW at baseline PTHrP measurement and during 
follow-up. Body mass index (BMI) was calculated as BW di-
vided by height squared (kg/m2). Lean body mass (LBM) and 
body fat mass (BFM) were calculated as: LBM (kg)=[9,270×
weight (kg)/(6,680+216×BMI)] in males; [9,270×weight (kg)/
(8,780+244×BMI)] in females [12]; BFM (%)=[(1.20×
BMI)+(0.23×age)–16.2] in males; [(1.20×BMI)+(0.23×age)–
5.4] in females [13]. BW change (% BW) was calculated as: 
[(follow-up weight–baseline weight)/baseline weight]×100. 
According to the international definition of cachexia [3], clini-
cally meaningful WL was defined as % BW <–5% or baseline 
BMI <20 kg/m2 plus % BW <–2%. 
Statistical analysis 
All statistical analyses were performed using SPSS version 20.0 
(IBM, Armonk, NY, USA). Baseline characteristics are reported 
as mean±standard deviation or number (percentage) of pa-
tients. Between-group differences were analyzed by indepen-
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dent t test or chi-square test. Change in BW from baseline to 
follow-up were presented as mean and 95% confidential inter-
val (CI), and paired t test was used to analyze the difference be-
tween detailed subgroups. Kaplan-Meier survival curves were 
used to examine the WL probability in each subgroup and were 
compared by log-rank tests. The relative risk for WL by PTHrP 
level was further determined using a multivariate Cox regres-
sion model. For all tests, a P<0.05 was considered statistically 
significant.  
RESULTS
Baseline characteristics
Baseline characteristics of the study population are described in 
Table 1. Participants were consisted of various cancers of the 
head and neck, respiratory, gastroesophageal, hepatopancreato-
biliary, breast, genitourinary, and hematologic systems (Supple-
mental Table S1). The mean age was 59.1±14.4 years and 
46.1% were male. When stratified by serum PTHrP levels, 140 
(63.9%) were PTHrP negative and 79 (36.1%) were PTHrP 
positive, ranging from 1.1 to 107.0 pmol/L. PTHrP positive 
subjects showed significantly lower BMI and BFM compared 
to the negative group. Percentages of advanced cancer (stage 4) 
and poor PS (ECOG 2 to 4) were also higher in the PTHrP posi-
tive group. In laboratory findings, PTHrP positive patients had 
significantly higher corrected calcium, lower serum phosphate 
and albumin levels, and elevated CRP levels. Numbers of 
PTHrP positive patients by cancer sites are shown in Supple-
mental Table S2. 
Comparison of body weight changes by PTHrP and 
baseline clinical factors
Fig. 1 shows BW changes during the follow-up period classified 
by serum albumin, calcium levels, cancer stage, and PS. When 
categorized by albumin levels, BW was reduced by 0.8% to 
4.3% (Fig. 1A). WL was greatest in PTHrP positive subjects 
with hypoalbuminemia, while subjects with negative PTHrP 
and normal albumin levels experienced the least change in 
weight. Similar patterns were observed in calcium subgroups 
(Fig. 1B) and WL was more significant in PTHrP positive sub-
jects regardless of serum corrected calcium levels. When 
grouped by cancer stage, the prevalence of WL was 0.2%, with 
the least in subjects with negative PTHrP and cancer stage 1 to 
3 (Fig. 1C). In the other three groups, the WL was greater and 
the differences from baseline were more prominent in stage 4 
PTHrP positive subjects. When categorized by PTHrP and PS 
(Fig. 1D), the pattern of reduced BW reduction showed similar 
pattern to the other groups. 
Independent predictive value of PTHrP for weight loss by 
subgroup 
After a median follow-up of 327 days (IQR, 188 to 423), 74 
subjects (33.8%) experienced clinically significant WL. To in-
vestigate whether prediction of WL by PTHrP is influenced by 
serum albumin, corrected calcium levels, cancer stage, or PS, 
further analyses were conducted. In Kaplan-Meier curves show-
Table 1. Baseline Characteristics of Study Participants by Se-
rum PTHrP Level
Variable
Study subjects (n=219)
P value
Total
PTHrP 
negative 
(n=140)
PTHrP 
positive 
(n=79)
Age, yr 59.1±14.4 59.7±14.8 58.1±13.6 0.446
Male sex 101 (46.1) 56 (40) 45 (57) 0.016a
Body mass index,  
kg/m2
23.0±3.5 23.5±3.6 22.3±3.2 0.013a
Lean body mass, kg 42.7±9.0 42.7±9.2 42.7±8.9 0.996
Body fat mass, % 30.8±7.8 32.2±8.0 28.4±7.1 0.001a
Cancer stage 4 98 (44.7) 45 (32.1) 53 (67.1) <0.001a
ECOG PS 0–1 135 (61.6) 101 (72.1) 34 (43.0) <0.001a
PTHrP, pmol/L 4.9±4.4 - 4.9±4.4 -
Corrected Ca, mg/dL 9.6±1.3 9.5±1.3 10.1±1.5 0.002a
Phosphate, mg/dL 3.5±1.1 3.6±1.1 3.2±0.9 0.014a
Albumin, g/dL 3.7±0.7 3.8±0.7 3.4±0.7 <0.001a
Hemoglobin, g/dL 10.9±1.9 11.0±1.9 10.7±2.0 0.188
Creatinine, mg/dL 1.4±1.7 1.5±2.0 1.2±1.2 0.077
eGFR, mL/min/ 
1.73 m2
88.9±55.0 86.7±58.2 92.9±49.6 0.427
C-reactive protein, 
mg/L
26.4±43.3 21.4±45.4 34.5±39.4 0.040a
Comorbidities
   CHF 18 (8.2) 11 (7.9) 7 (8.9) 0.783
   COPD 6 (2.7) 2 (1.4) 4 (5.1) 0.191
   Diabetes mellitus 71 (32.4) 48 (34.3) 23 (29.1) 0.453
   Liver cirrhosis 15 (6.8) 10 (7.1) 5 (6.3) 0.829
Values are expressed as mean±SD or number (%). P values are by in-
dependent t test or chi-square test. 
PTHrP, parathyroid hormone-related peptide; ECOG PS, Eastern Coop-
erative Oncology Group Performance Status; eGFR, estimated glomer-
ular filtration rate; CHF, congestive heart failure; COPD, chronic ob-
structive pulmonary disease.
aStatistical significance values. 
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ing WL-free probability of each subgroup, PTHrP negative sub-
jects had a 2- to 3-fold significantly better WL-free survival 
compared to PTHrP positive subjects irrespective of serum al-
bumin, corrected calcium level, and cancer stage (log-rank, 
P<0.05) (Fig. 2A-F). In patients with stage 4 cancer, the differ-
ence was less pronounced, but still statistically significant. 
When stratified by PS, individuals with better functional capac-
ity (ECOG 0 to 1) were the most influenced by the presence of 
PTHrP in predicting WL (hazard ratio [HR], 4.00; 95% CI, 3.34 
to 20.60) (Fig. 2G). However, patients with poorer PS (ECOG 2 
to 4) showed a generally low probability of WL-free survival 
compared to those who were ECOG 0 to 1, and were not affect-
ed by the presence of PTHrP (HR, 1.06; 95% CI, 0.56 to 2.01) 
(Fig. 2H). 
In multivariate Cox regression analysis adjusted for age, base-
line BMI, serum albumin, corrected calcium level, cancer stage 
and PS (Table 2), the presence of PTHrP significantly predicted 
the WL (HR, 2.06; 95% CI, 1.27 to 3.34) in cancer patients. The 
effect of PTHrP on WL was more remarkable in subjects with 
lower albumin levels (HR, 2.49; 95% CI, 1.30 to 4.75), stage 4 
cancer (HR, 2.17; 95% CI, 1.15 to 4.11), and better PS (HR, 
2.62; 95% CI, 1.22 to 5.63). The effect of PTHrP on WL was at-
tenuated with no statistical significance in normal albumin lev-
els and stage 1 to 3 cancer patients. In addition, regardless of 
calcium levels, the effect of PTHrP on WL was maintained; 
however, hypercalcemia and PTHrP positivity showed additive 
effects on WL ([HR, 1.93; 95% CI, 1.10 to 3.37] and [HR, 3.12; 
95% CI, 1.19 to 8.16], respectively).  
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Fig. 1. Body weight changes from baseline to follow-up (FU) by subgroup. Patients are grouped by serum parathyroid hormone-related pep-
tide (PTHrP) and (A) corrected calcium, (B) albumin, (C) cancer stage, (D) performance status. Data are expressed as box and range bar 
plots representing the mean and 95% confidence interval (CI). Black and gray plots represent the PTHrP negative group and PTHrP positive 
group, respectively. Mean % change was calculated as ([FU weight–baseline weight]/baseline weight×100) for each group. Base, baseline; 
ECOG, Eastern Cooperative Oncology Group. aP values by paired t test <0.05; bP values by paired t test <0.005.
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Fig. 2. Cumulative Kaplan-Meier curves for weight loss (WL)-free probability by parathyroid hormone-related peptide levels. Patients with 
(A) serum albumin ≥3.7 g/dL, (B) serum albumin <3.7 g/dL, (C) corrected calcium <10.5 mg/dL, (D) corrected calcium ≥10.5 mg/dL, (E) 
cancer stage 1 to 3, (F) cancer stage 4, (G) Eastern Cooperative Oncology Group (ECOG) 0 to 1, (H) ECOG 2 to 4. HR, hazard ratio; CI, 
confidence interval. aLog rank P<0.05; bLog rank P<0.005.
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DISCUSSION
In this study we investigated the differential impact of clinical 
and laboratory factors on PTHrP-related WL in patients with 
cancer. By detailed subgroup analyses, we revealed that lower 
albumin levels (<3.7 g/dL), hypercalcemia (≥10.5 mg/dL), and 
cancer stage 4 reinforced the effect of PTHrP on WL by 2- to 3- 
fold. Patients with good nutritional status (albumin ≥3.7 g/dL) 
or cancer stage 1 to 3 were not significantly affected by PTHrP. 
In addition, WL occurred within a short period of time in pa-
tients who required considerable assistance (ECOG 2 to 4), but 
the impact of PTHrP on WL was not significant. 
Cancer cachexia has been known to negatively impact pa-
tients’ quality of life, treatment outcome, and survival [4]. Pa-
tients with cachexia experience a reduced ability to tolerate che-
motherapy or radiotherapy along with a decrease in physical 
functioning, which finally leads to increased morbidity and 
mortality and is attributable for 20% of cancer-related deaths 
[2,4]. Also, cachexia is associated with psychological stress and 
increased hospitalization stay and cost [4,14]. Therefore, while 
early recognition and proper interventions to delay or reduce the 
deleterious effects of cachexia are needed, cachexia remains 
largely under-recognized and untreated [15,16].
In our study, the effect of PTHrP on cancer cachexia was po-
tentiated in subjects with hypercalcemia (HR; hypercalcemia 
3.12 vs. normocalcemia 1.93). As tumor burden worsened, pro-
duction of tumor-derived inflammatory cytokines increased and 
likely collaborated with PTHrP to alter energy regulation into 
promoting loss of muscle and adipose tissue [17]. Likewise, as 
hypercalcemia occurs more frequently in widespread metastatic 
disease, or in the presence of tumor-produced substances such 
as prostaglandin or osteoclast activating factor [18], the interac-
tion with PTHrP might aggravate wasting in these patients. A 
previous study also showed that injecting PTHrP produced dif-
ferent effects on WL according to underlying health conditions; 
healthy mice were not affected by PTHrP, while tumor-bearing 
mice experienced activation of atrophy-related genes and exac-
erbation of muscle wasting after PTHrP injection [8]. These 
findings support the notion that PTHrP action on cancer cachex-
ia might depend on other tumor-derived factors. Also, as an-
orexia is more common in patients with advanced cancer, poor 
calorie intake with elevated PTHrP could aggravate cancer ca-
chexia [5]. 
Regarding the role of nutritional support in cancer patients, 
the results are controversial [19-22]. A meta-analysis showed 
that oral nutritional supplements in malnourished cancer pa-
tients was helpful to increase fat mass or quality of life, but had 
no effect on mortality [19]. In contrast, other meta-analysis 
demonstrated that total parenteral nutrition in cancer patients 
was beneficial in reducing postoperative surgical complications 
and operative mortality [20], and some studies revealed that 
cancer patients with nutritional intervention experienced less 
WL after treatment [21,22]. Although cachexia cannot be fully 
reversed by nutritional support, our study showed that the ad-
verse effect of PTHrP was greater in patients with low albumin 
levels, an indication of nutritionally poor status. Therefore, early 
dietary counseling and proper nutritional supplementation in 
PTHrP positive individuals should be considered. 
Poor PS group did not affected by PTHrP in predicting WL, 
which is contrary to other findings that PTHrP had a greater in-
fluence on patients with poor health status (stage 4 cancer, hy-
percalcemia, and hypoalbuminemia). There is no conclusive ex-
planation, but PTHrP is thought to have no impact because 
PTHrP-associated wasting preceded the decline in PS. It is 
known that browning of adipose tissue and increased energy ex-
penditure occurs in an early pathophysiology in cachexia [23], 
Table 2. Independent Predictive Value of PTHrP for Weight 
Loss: Subgroup Analyses
Dependent variable 
Weight lossa
Hazard ratio 95% CI P value
Total (n=219)
   PTHrP, pmol/L 2.06b 1.27–3.34b 0.003b
Subgroup analysis 
   Serum albumin levels, g/dL
      Albumin ≥3.7 (n=113) 1.38 0.61–3.12 0.439
      Albumin <3.7 (n=106) 2.49b 1.30–4.75b 0.006b
   Serum calcium levels, mg/dL
      Corrected Ca <10.5 (n=169) 1.93b 1.10–3.37b 0.022b
      Corrected Ca ≥10.5 (n=50) 3.12b 1.19–8.16b 0.021b
   Cancer stage
      Stage 1–3 (n=121) 2.11 0.93–4.75 0.073
      Stage 4 (n=98) 2.17b 1.15–4.11b 0.017b
   Performance status
      ECOG 0–1 (n=135) 2.62b 1.22–5.63b 0.013b
      ECOG 2–4 (n=84) 0.97 0.51–1.88 0.938
PTHrP, parathyroid hormone-related peptide; CI, confidence interval; 
ECOG, Eastern Cooperative Oncology Group. 
aAdjusted for age, baseline body mass index, serum albumin, corrected 
calcium level, cancer stage, and performance status; bStatistical signifi-
cance values.
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and that PTHrP is associated with thermogenesis in adipose tis-
sue [8]. Also, there is a steep slope of WL-free probability in 
ECOG 2 to 4 subjects compared to ECOG 0 to 1 in our Kaplan-
Meier curve (Fig. 2G, H), indicating that WL occurred within a 
shorter period of time by various factors stronger than PTHrP. 
Therefore, this study results should be limited to patients with 
good performance. 
Our study has some limitations. First, due to the absence of 
data, we could not evaluate dietary intake, anorexia, or exercise, 
which can influence weight change. Second, laboratory findings 
and PS can change over time, but these changes are not reflect-
ed in our analyses. Third, as PTHrP is not a universal protein se-
creted from all types of cancer, our findings should be more fo-
cused on PTHrP-producing cancers, such as head and neck, re-
spiratory system, hepatopancreatobiliary, breast, genitourinary, 
and hematologic malignancy. Despite these limitations, consid-
ering the importance of early recognition of cancer cachexia, 
these findings suggest that patients with certain characteristics 
are vulnerable to PTHrP-associated WL and may serve to facili-
tate a comprehensive management approach. 
In summary, our results suggest that prediction of WL by 
PTHrP among patients with cancer might be affected by serum 
calcium or albumin levels, PS, and cancer stage. Early identifi-
cation and management of cachexia is needed in PTHrP positive 
patients, especially those with advanced cancer stage accompa-
nied by hypercalcemia or hypoalbuminemia.  
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